PL2101569T3 - Stała, krystaliczna zasada rasagaliny - Google Patents
Stała, krystaliczna zasada rasagalinyInfo
- Publication number
- PL2101569T3 PL2101569T3 PL07862906T PL07862906T PL2101569T3 PL 2101569 T3 PL2101569 T3 PL 2101569T3 PL 07862906 T PL07862906 T PL 07862906T PL 07862906 T PL07862906 T PL 07862906T PL 2101569 T3 PL2101569 T3 PL 2101569T3
- Authority
- PL
- Poland
- Prior art keywords
- crystalline solid
- rasagiline base
- solid rasagiline
- base
- aminoindan
- Prior art date
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 1
- 229960000245 rasagiline Drugs 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/82—Purification; Separation; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87501106P | 2006-12-14 | 2006-12-14 | |
| EP07862906A EP2101569B1 (en) | 2006-12-14 | 2007-12-13 | Crystalline solid rasagiline base |
| PCT/US2007/025583 WO2008076348A1 (en) | 2006-12-14 | 2007-12-13 | Crystalline solid rasagiline base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2101569T3 true PL2101569T3 (pl) | 2012-03-30 |
Family
ID=39536623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07862906T PL2101569T3 (pl) | 2006-12-14 | 2007-12-13 | Stała, krystaliczna zasada rasagaliny |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US7750051B2 (pl) |
| EP (1) | EP2101569B1 (pl) |
| JP (1) | JP5623081B2 (pl) |
| KR (1) | KR101459744B1 (pl) |
| CN (1) | CN101557706B (pl) |
| AT (1) | ATE528989T1 (pl) |
| AU (1) | AU2007334428B2 (pl) |
| CA (1) | CA2672414A1 (pl) |
| CY (1) | CY1112511T1 (pl) |
| DK (1) | DK2101569T3 (pl) |
| EA (1) | EA016820B1 (pl) |
| ES (1) | ES2375761T3 (pl) |
| HK (1) | HK1129276A1 (pl) |
| HR (1) | HRP20110980T1 (pl) |
| IL (1) | IL198985A0 (pl) |
| MX (1) | MX2009006251A (pl) |
| NO (1) | NO20092611L (pl) |
| NZ (1) | NZ577460A (pl) |
| PL (1) | PL2101569T3 (pl) |
| PT (1) | PT2101569E (pl) |
| RS (1) | RS52183B (pl) |
| SI (1) | SI2101569T1 (pl) |
| UA (1) | UA97502C2 (pl) |
| WO (1) | WO2008076348A1 (pl) |
| ZA (1) | ZA200903903B (pl) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2574925A1 (en) * | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
| US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| RS52867B (en) * | 2005-02-17 | 2013-12-31 | Teva Pharmaceutical Industries Ltd. | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS |
| MX2007010233A (es) | 2005-02-23 | 2007-11-07 | Teva Pharma | Formulaciones de rasagilina de uniformidad de contenido mejorada. |
| EP1954667B1 (en) * | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| WO2007098264A2 (en) * | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| CA2646250A1 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| JP5623081B2 (ja) * | 2006-12-14 | 2014-11-12 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶質固体のラサジリン塩基 |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| EP2194780A4 (en) * | 2007-09-05 | 2010-10-27 | Teva Pharma | METHOD FOR TREATING GLAUCOMA BY RASAGILINE |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| CA2723869C (en) | 2008-06-02 | 2013-07-16 | Generics [Uk] Limited | A process for the preparation of enantiomerically pure amines |
| WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| JP2011522892A (ja) * | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | パーキンソン病緩和のためのラサギリン |
| BRPI0909997A2 (pt) | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| CN101606923B (zh) * | 2008-06-20 | 2013-01-09 | 重庆医药工业研究院有限责任公司 | 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法 |
| ITMI20081406A1 (it) * | 2008-07-29 | 2010-01-30 | Dipharma Francis Srl | Forma cristallina di rasagilina e procedimento per la sua preparazione |
| EP2358658A4 (en) * | 2008-11-20 | 2012-11-14 | Reddys Lab Ltd Dr | PREPARATION OF RASAGILIN AND ITS SALTS |
| EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| US20100189790A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| JP2012532843A (ja) | 2009-07-09 | 2012-12-20 | ラティオファーム ゲーエムベーハー | ラサギリンの塩およびその製剤 |
| EP2298277A1 (en) * | 2009-09-09 | 2011-03-23 | Labtec GmbH | Transdermal patch formulation |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| EP2325159A1 (en) | 2009-11-24 | 2011-05-25 | LEK Pharmaceuticals d.d. | Novel salts of rasagiline |
| AU2010341499A1 (en) | 2009-12-22 | 2012-08-09 | Teva Pharmaceutical Industries Ltd. | 3-keto-N-propargyl-1-aminoindan |
| WO2011121607A2 (en) | 2010-03-29 | 2011-10-06 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
| UA103851C2 (en) | 2010-04-30 | 2013-11-25 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Propylaminoindan transdermal composition |
| CA2806740A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| WO2012153349A2 (en) | 2011-05-04 | 2012-11-15 | Cadila Healthcare Limited | Rasagiline and its pharmaceutically acceptable salts |
| BR112014008552A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-metil-propargilaminoindano |
| AU2012323349A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
| EP2776020B1 (en) | 2011-11-09 | 2019-09-11 | Teikoku Seiyaku Co., Ltd. | Methods for the treatment of skin neoplasms |
| EP2610239A1 (en) | 2012-01-02 | 2013-07-03 | Dr. Reddy's Laboratories Ltd. | Preparation Of Rasagiline Hemitartrate |
| EA201491734A1 (ru) | 2012-03-21 | 2015-01-30 | Синтон Бв | Стабилизированные фармацевтические композиции, содержащие соли разагилина |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
| EA031621B1 (ru) * | 2012-11-02 | 2019-01-31 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Трансдермальная композиция на основе пропиниламиноиндана, содержащий такие композиции набор и способ доставки пропиниламиноиндана |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4252951A (en) * | 1979-10-09 | 1981-02-24 | Eli Lilly And Company | Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid |
| US4529811A (en) * | 1981-03-02 | 1985-07-16 | G. D. Searle & Co. | Process for isolating organic compounds and lithium salt complexes useful in said process |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| CN1031995C (zh) * | 1991-01-02 | 1996-06-12 | 奥韦特有限公司 | N-炔丙基-1-氨基茚满的r-对映体的制法 |
| IL112819A (en) | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
| IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US5914349A (en) | 1994-01-10 | 1999-06-22 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| HU224354B1 (hu) | 1995-02-01 | 2005-08-29 | Pharmacia & Upjohn Company | 2-Aminoindán-származékok alkalmazása és az ezeket tartalmazó gyógyszerkészítmények |
| IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| US5663415A (en) | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
| IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69732984T2 (de) | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| AU2472499A (en) | 1998-01-27 | 1999-08-09 | Thomas N. Thomas | Methods of treatment using mao-a and mao-b inhibitors such as l-deprenyl |
| DE10041478A1 (de) | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| IL141690A (en) * | 2001-02-27 | 2004-06-20 | Isp Finetech Ltd | Process for preparation of rasagiline and its salts |
| US6543155B2 (en) | 2001-03-01 | 2003-04-08 | National Agricultural Research Organization | Freeze-dried product and process and apparatus for producing it |
| WO2003039525A1 (en) * | 2001-11-05 | 2003-05-15 | Krele Pharmaceuticals Llc | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism |
| US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
| US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| UA78854C2 (en) * | 2002-09-06 | 2007-04-25 | Kissei Pharmaceutical | Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same |
| ES2588780T3 (es) | 2002-11-15 | 2016-11-04 | Teva Pharmaceutical Industries Limited | Uso de rasagilina con o sin riluzol para el tratamiento de la esclerosis lateral amiotrófica |
| US20040157784A1 (en) | 2003-02-10 | 2004-08-12 | Jame Fine Chemicals, Inc. | Opiod tannate compositions |
| DE602004024417D1 (de) | 2003-09-03 | 2010-01-14 | Glaxo Group Ltd | Neues verfahren zur herstellung von pleuromutilinderivaten |
| US7799273B2 (en) * | 2004-05-06 | 2010-09-21 | Smp Logic Systems Llc | Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes |
| CA2574925A1 (en) | 2004-07-26 | 2006-02-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms including rasagiline |
| RU2389482C2 (ru) | 2004-11-24 | 2010-05-20 | Тева Фармасьютикал Индастриз, Лтд. | Композиции разагилина, распадающиеся в ротовой полости |
| US20090111892A1 (en) * | 2004-11-24 | 2009-04-30 | Shulamit Patashnik | Rasagiline Orally Disintegrating Compositions |
| MX2007010233A (es) | 2005-02-23 | 2007-11-07 | Teva Pharma | Formulaciones de rasagilina de uniformidad de contenido mejorada. |
| EP1954667B1 (en) | 2005-11-17 | 2017-02-08 | Teva Pharmaceutical Industries Ltd | Methods for isolating propargylated aminoindans |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| WO2007098264A2 (en) | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| CN101032474B (zh) | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| CA2646250A1 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| US7573834B2 (en) * | 2006-05-31 | 2009-08-11 | Alcatel Lucent | Method and system for allocating a group bit rate among multiple bonded pairs in a communications network |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| AU2007334493B2 (en) | 2006-12-14 | 2010-12-02 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
| JP5623081B2 (ja) | 2006-12-14 | 2014-11-12 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶質固体のラサジリン塩基 |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| EP2194780A4 (en) | 2007-09-05 | 2010-10-27 | Teva Pharma | METHOD FOR TREATING GLAUCOMA BY RASAGILINE |
| US8188149B2 (en) | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| US20110117200A1 (en) | 2008-03-31 | 2011-05-19 | Actavis Group Ptc Ehf | Rasagiline mesylate particles and process for the preparation thereof |
| WO2009151594A1 (en) | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
| BRPI0909997A2 (pt) | 2008-06-19 | 2015-10-27 | Teva Pharma | r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189790A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
| JP2012532843A (ja) | 2009-07-09 | 2012-12-20 | ラティオファーム ゲーエムベーハー | ラサギリンの塩およびその製剤 |
| EP2485722A1 (en) | 2009-10-09 | 2012-08-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of progressive supranuclear palsy |
| AU2010341499A1 (en) * | 2009-12-22 | 2012-08-09 | Teva Pharmaceutical Industries Ltd. | 3-keto-N-propargyl-1-aminoindan |
| AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| CA2806740A1 (en) * | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| JP2014503480A (ja) * | 2010-10-26 | 2014-02-13 | テバ ファーマシューティカル インダストリーズ リミティド | ジュウテリウムリッチなラサギリン |
| BR112014008552A2 (pt) * | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-metil-propargilaminoindano |
| KR20140074388A (ko) * | 2011-10-10 | 2014-06-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라사길린 시트라마이드 |
| AU2012323349A1 (en) * | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
-
2007
- 2007-12-13 JP JP2009541390A patent/JP5623081B2/ja not_active Expired - Fee Related
- 2007-12-13 WO PCT/US2007/025583 patent/WO2008076348A1/en active Application Filing
- 2007-12-13 EP EP07862906A patent/EP2101569B1/en active Active
- 2007-12-13 PL PL07862906T patent/PL2101569T3/pl unknown
- 2007-12-13 EA EA200970581A patent/EA016820B1/ru not_active IP Right Cessation
- 2007-12-13 PT PT07862906T patent/PT2101569E/pt unknown
- 2007-12-13 NZ NZ577460A patent/NZ577460A/en unknown
- 2007-12-13 ES ES07862906T patent/ES2375761T3/es active Active
- 2007-12-13 RS RS20120016A patent/RS52183B/en unknown
- 2007-12-13 ZA ZA200903903A patent/ZA200903903B/xx unknown
- 2007-12-13 AU AU2007334428A patent/AU2007334428B2/en not_active Ceased
- 2007-12-13 SI SI200730807T patent/SI2101569T1/sl unknown
- 2007-12-13 US US12/002,082 patent/US7750051B2/en not_active Expired - Fee Related
- 2007-12-13 AT AT07862906T patent/ATE528989T1/de active
- 2007-12-13 MX MX2009006251A patent/MX2009006251A/es active IP Right Grant
- 2007-12-13 KR KR1020097014006A patent/KR101459744B1/ko not_active IP Right Cessation
- 2007-12-13 CA CA002672414A patent/CA2672414A1/en not_active Abandoned
- 2007-12-13 UA UAA200906360A patent/UA97502C2/ru unknown
- 2007-12-13 CN CN2007800458662A patent/CN101557706B/zh not_active Expired - Fee Related
- 2007-12-13 DK DK07862906.0T patent/DK2101569T3/da active
-
2009
- 2009-05-27 IL IL198985A patent/IL198985A0/en unknown
- 2009-07-08 NO NO20092611A patent/NO20092611L/no not_active Application Discontinuation
- 2009-10-13 HK HK09109428.4A patent/HK1129276A1/xx not_active IP Right Cessation
-
2010
- 2010-01-08 US US12/655,827 patent/US8614252B2/en not_active Expired - Fee Related
- 2010-01-08 US US12/655,828 patent/US20100144887A1/en not_active Abandoned
-
2011
- 2011-12-29 HR HR20110980T patent/HRP20110980T1/hr unknown
-
2012
- 2012-01-11 CY CY20121100022T patent/CY1112511T1/el unknown
-
2014
- 2014-08-14 US US14/459,877 patent/US20150038744A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200903903B (en) | Crystalline solid rasagiline base | |
| HK1129277A1 (en) | Tannate salt of rasagiline | |
| MX2010002974A (es) | Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida. | |
| MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
| PH12015500550A1 (en) | Anti-notch1 nrr antibodies and methods using same | |
| TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
| WO2007019439A3 (en) | Block copolymer compositions and uses thereof | |
| TW200716512A (en) | Processes for preparing cinacalcet hydrochloride crystal form I | |
| TW200608973A (en) | Rapamycin polymorph Ⅱ and uses thereof | |
| JO2778B1 (en) | Certain vehicles, installations and methods | |
| WO2007127834A3 (en) | Compositions and methods of preparation thereof | |
| HK1124548A1 (en) | Human anti-il-23 antibodies, compositions, methods and uses il-23 | |
| MY148286A (en) | Freeze-dried, aerated dairy or dairy-substitute compositions and methods of making thereof | |
| WO2009025876A3 (en) | Crystalline forms of erlotinib hcl and formulations thereof | |
| WO2009067674A3 (en) | Polymorphs of sunitinib base and processes for preparation thereof | |
| WO2008057291A3 (en) | Crystalline and amorphous imatinib base, imatinib mesylate- and processes for preparation thereof | |
| PL2079446T3 (pl) | Preparat paliperidonu o przedłużonym uwalnianiu | |
| TW200738649A (en) | Calcilytic compounds | |
| TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
| EP2644614A3 (en) | Solid state forms of 5-azacytidine and processes for preparation thereof | |
| WO2006091836A8 (en) | Formulations of ladostigil tartrate | |
| TW200638932A (en) | CCI-779 polymorph and use thereof | |
| TW200637804A (en) | Substantially pure tolterodine tartrate and process for preparing thereof | |
| WO2008015584A3 (en) | Improved process for synthesizing desvenlafaxine free base and salts or solvates thereof | |
| WO2009025792A3 (en) | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof |